The Hunterbrook report alleged that ENSG inflated CMS star ratings — a key metric that drives reimbursement rates and investor confidence. On the Company's Q1 2026 earnings call on May 1, 2026, CEO Barry Port stated that "85% of all of our operations are at 4- or 5-star quality measures." The short-seller report directly challenged the accuracy of those quality metrics, alleging that the ratings were the product of systematic data manipulation rather than genuine clinical performance.
The report also alleged improper related-party billing practices at the company's network of skilled nursing facilities. Prior to the report's publication, on June 2, 2026, a director filed a Form 144 attesting that "he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." The stock declined sharply in the session following the Hunterbrook publication.
To receive more information, please fill out the form.
